CRCx-S PAA Potent antiviral antibody
CRCx-S PAA (Potent antiviral antibody) a molecule that straitjackets the crucial SARS-CoV-2 machinery that allows the virus to infect our cells. These molecules could be self- administered with a nasal spray or inhaler. Used a day, could provide powerful, reliable protection against SARS-CoV-2 until a vaccine becomes available. Viral cause respiratory manifestations (SARS-CoV-2). … Mode of action: The nasopharynx is the area with the highest SARS-CoV-2 concentration, which would explain the high spread of the virus, leading to many attempts to produce an effective antiviral nasal spray. CRCx-S PAA hopes to buck the trend, claiming that the product is unique in blocking the process by which the virus binds itself to receptors in the nasal passage. CRCx-S PAA is an antibodies immunomodulators for the prevention of respiratory viral and infections. CRCx-S PAA has antiviral capacity and apparent safety for use in mucosa, at present, CRCx-S PAA comprises Neutralizing antibodies that can bind to virus coated membrane and block their ability to trigger the infection when we spayed it through the nasal cavity. CRCX-S PAA is a polyclonal antibody that can neutralize the Covid-19 virus, once it enters or during viral infection CRCx-S PAA interrupt the passage of SARS-Cov-2 across the target cell mediated by ACE2 receptor. CRCx-S PAA monoclonal therapy rapidly reduced viral load and associated symptoms in infected COVID-19 patients. CRCx-S PAA monoclonal therapy was designed in spray form specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.